Table 1 Characteristics of participants at study baseline
Characteristic | Placebo (n = 61) | MAG-EPA (n = 60) |
|---|---|---|
Cancer characteristics | ||
PSA at randomization (ng/ml) | ||
Mean (Std) | 6.69 (5.66) | 8.69 (9.48) |
Min, max | 0.32, 39.00 | 0.83, 56.00 |
Median (Q1, Q3) | 5.77 (4.05, 7.00) | 6.11 (4.40, 8.81) |
ISUP grade group, n (%) | ||
2 (Gleason 3 + 4) | 37 (60.66) | 28 (46.67) |
3 (Gleason 4 + 3) | 18 (29.51) | 17 (28.33) |
4 (Gleason 8) | 5 (8.20) | 11 (18.33) |
5 (Gleason 9) | 1 (1.64) | 4 (6.67) |
Cancer Stage n (%) | ||
T2a or less | 56 (90.16) | 48 (80.00) |
T2b or T2c | 3 (4.92) | 4 (6.66) |
T3 or more | 3 (4.92) | 8 (13.33) |
NCCN risk, n (%) | ||
Intermediate | 51 (83.61) | 42 (70.00) |
High | 10 (16.39) | 18 (30.00) |
Patient characteristics | ||
Age (years) | ||
Mean (Std) | 62.7 (7.44) | 64.9 (6.39) |
Body mass index (m/kg2) | ||
Mean (Std) | 27.45 (4.43) * | 28.74 (3.65) † |
Smoking status | ||
Current (%) | 8 (13.11) | 3 (5.00) |
Past (%) | 24 (39.34) | 30 (50.00) |
Never (%) | 29 (47.54) | 26 (43.33) |
Missing value | 0 (0.00) | 1 (1.67) |
Education, n (%) | ||
High school or less | 18 (29.51) | 23 (38.33) |
Postsecondary diploma | 24 (39.34) | 16 (26.67) |
University degree | 18 (29.51) | 19 (31.67) |
Missing | 1 (1.64) | 2 (3.33) |
RBC fatty acid profile (%) ‡ | ||
Total ω3 | ||
Mean (Std) | 7.36 (0.97) | 7.40 (1.15) |
Median (Q1, Q3) | 7.31 (6.70, 7.93) | 7.25 (6.54, 8.08) |
LCω3 | ||
Mean (Std) | 7.06 (0.98) | 7.10 (0.23) |
Median (Q1, Q3) | 7.05 (6.47, 7.65) | 6.90 (6.26, 7.74) |
EPA | ||
Mean (Std) | 0.80 (0.24) | 0.73 (0.23) |
Median (Q1, Q3) | 0.79 (0.62, 0.90) | 0.66 (0.57, 0.83) |
Total ω6 | ||
Mean (Std) | 26.64 (1.30) | 26.47 (1.50) |
Median (Q1, Q3) | 26.53 (25.69, 27.57) | 26.71 (25.45, 27.41) |
ω6:ω3 ratio | ||
Mean (Std) | 3.70 (0.64) | 3.68 (0.70) |
Median (Q1, Q3) | 3.61 (3.23, 4.08) | 3.69 (3.21, 4.14) |
